We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Jabs for youngest children offer potential new market amid global glut of adult doses
Pharma group’s chief is right to take advantage of the market sell-off to boost pipeline
US pharmaceutical group’s biggest deal in more than 5 years comes as sales of its Covid vaccine are set to fall
Proxy advisers back shareholder resolutions as new shot shows promising results
Remuneration at the three big jab makers reflects surge in value of share options
Johnson government announces plan after similar moves in Scotland and Wales
US drugs regulator says it needs more time to evaluate low-dose jab for children under 5
Company projects $54bn in sales from Covid vaccine and treatment but some experts predict pandemic has peaked
First human study of variant-specific jab by big western drugmaker could prompt shift in manufacturing
Early findings suggest level of antibodies needed to protect against variant ‘too high’ for jab to induce
Investors push for higher price or spin-off after rejecting Unilever’s £50bn offer
The division jointly owned by Pfizer is due to be spun off in London listing later this year
Asset managers call for pharma executive pay to be linked to equitable distribution of jabs
Drugmakers set to take on GSK as they aim to replicate Covid jab success
New mRNA technology could make jabs better-matched to different annual strains and improve efficacy
Complex nature of drug means it will take more than half a year to make the 10m courses that are on order
Data confirm Paxlovid cuts risk of hospitalisation or death by 89% for highly vulnerable patients
Report suggests share of cases that develop into severe disease should be lower than in previous waves
Awards highlights include: law-firm people strategies; life after Libor; and the most innovative law firms and individuals
Urgency on issues such as vaccine development and climate change has brought permanent change. Plus: FT most innovative in-house legal teams
Preliminary research suggests two shots show significantly reduced effectiveness against new coronavirus variant
Executive says patients on other medications will not be able to take competing antiviral treatment
Plus, corporate political donations rise up the governance agenda and regulators eye sustainability-linked derivatives
Research shows mRNA vaccines from Pfizer and Moderna are by far most effective third doses
Drugmakers are stress-testing existing jabs while preparing new formulas
International Edition
